Results 12,061-12,080 of 32,978 for speaker:Catherine Connolly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Going back to Galway, for example, or any hospital, and independent reviews, something happens, such as an adverse clinical event, there are internal reviews - I am not talking about those – and eventually there is an external review. If we take the case of Savita Halappanavar, for example, eventually we got to an external independent review. Is that not right?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Okay. I have asked a simple question on the factual position on the ground of how many reviews there were and the cost of them. That is very important leading into the State Claims Agency, because what are the hospitals learning from these reviews? Now, I am told that they have no knowledge, they have no record, of how many independent reviews there were and the cost of them. Maybe there...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I understand that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I am asking for clarification from the Department, if it is able, and from the State Claims Agency. Quite clearly the agency has no input in this, but down the road it lands on Mr. Breen’s desk because cases arise out of those facts. Where is the learning process if there is no record of the facts and the review?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: However, if there is no record or cost analysis of the independent review, is somebody falling down somewhere? Mr. Breen cannot comment on it, but it certainly ends up on his desk because cases arise out of it. I will finish with two final points. One concerns maternity. To clarify, there is the general indemnity scheme and the clinical indemnity scheme. The clinical scheme covers...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Does the clinical indemnity scheme cover Tusla?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Very well.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I can think of such cases straight away, without mentioning them.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I also wish to refer to the thalidomide cases. I know this took place a long time ago but it has effects right down to the present day. There was an issue around the Statute of Limitations.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: One issue, which we have now clarified, concerned mediation. The other concerned the Statute of Limitations, which another member asked about. Mr. Breen said that the State Claims Agency is under a duty and is obliged to seek the protection of the Statute of Limitations.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I wished to clarify that. That was another cause of concern in the letter. I will finish on the point of thalidomide. I wish to understand clearly, having read the letters. A number of people suffered as a result of mothers taking thalidomide. The State comes into this because at the time there was a question as to whether it should have taken the product off the market sooner. That is...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: It is similar to the cervical smear cases. The State did not disclose information it had in time. The potential liability arises from the same point. Is that right?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: The State is potentially liable for not acting quickly enough. That is how the SCA is involved in this. It is not just the German company and the Irish distributor.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I am not speaking personally, but it seems to me that the State has not covered itself in glory in how it has treated the mothers and children who have suffered as a result of this. We are discussing this in 2018. This took place in 1960 or 1961, did it not?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: The issue concerns when it should have been taken off the shelf. How often has mediation been used in those cases?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Yes.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: Until December 2016.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I know that. Is Mr. Breen in a position to say how often mediation was used and how often cases were settled as a result of mediation?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: No, I refer to cases concerning thalidomide.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Catherine Connolly: I see. It was on behalf of the group.